Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging (2024)

Peer-Reviewed Study · Poudel SB, Frikha-Benayed D, Ruff RR, Yildirim G, Dixit M, Korstanje R, et al. · March 25, 2024

Poudel SB et al., 2024-03-25: Aging study in aged C57BL/6J and UM-HET3 mice given long-term oral methylene blue (6-12 months) finding no effect on age-related bone loss or bone morphology, despite in-vitro benefit.

Although we observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss.

abstract

Poudel SB et al., 2024-03-25: Aging study in aged C57BL/6J and UM-HET3 mice given long-term oral methylene blue (6-12 months) finding no effect on age-related bone loss or bone morphology, despite in-vitro benefit. Study type: in-vitro plus controlled animal study. N: 18-month-old female C57BL/6J mice plus adult male and female UM-HET3 mice (group sizes per paper). Country: USA. Dose and schedule: MB in diet from 18 months for 6 or 12 months, and from 7 to 22 months in UM-HET3. Route: oral, in feed. Comparator: untreated and MitoQ-treated mice. Funder: NIA P30 AG038070, R01 AG056397, U01 AG022303, U01 AG022308, NIAMS R01 AR070547, R01 AR041210 and others. Declared conflicts: none. Direct ageing-endpoint test in vivo with a null result. Study type: animal.